What's New


License Agreement Has Been Entered with Asahi Kasei Corp.

We executed a worldwide license agreement with Asahi Kasei Corp. (Tokyo, Japan) for the use of iPS cell-derived cartilage for regenerative therapy of traumatic articular cartilage damage, the license allowing exclusive and non-exclusive rights, respectively, on the patents related to chondrocyte induction and those related to iPS cell technology, for all of which sublicensing rights have been granted to us by Kyoto University.

Asahi Kasei

Back to top